Treatment of Ocular Surface Inflammations

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age4-60
SponsorSemmelweis University

About this trial

The goal of this clinical trial is to learn if topical Cyclosporine 1% works to treat severe allergic ocular surface inflammation in pediatric population. The study will evaluate the efficacy and safety of topical Cyclosporine 1%.

The main questions it aims to answer are:

Does topical Cyclosporine 1% lower the number of times participants need to use a rescue steroid? What medical problems do participants have when taking topical Cyclosporine 1%?

Participants will:

Take topical Cyclosporine 1% every day for months. Visit the clinic once every 2-6 weeks for checkups and tests. Keep a diary of their symptoms and the number of times they use a rescue medication. spelling errors/typos and update as appropriate.

Eligibility criteria

Qualifiers

ocular surface inflammatory disease cornea inflammation -keratitis

Disqualifiers

eye surgery within 1 year, lack of fitness for the objective ocular surface measurments

Trial design

Treatments tested in this trial

  • Topical Cyclosporine 1%

Treatment groups

50 Participants
are divided into 2 treatment groups

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

Semmelweis University Department of OphthalmologyRecruiting1085, Budapest, Pest CountyHungaryHungary

Sponsors and collaborators